Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Invested Capital (2020 - 2025)

Historic Return on Invested Capital for Keros Therapeutics (KROS) over the last 5 years, with Q3 2025 value amounting to 0.06%.

  • Keros Therapeutics' Return on Invested Capital changed N/A to 0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year change of. This contributed to the annual value of 0.47% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Return on Invested Capital is 0.06%.
  • Over the past 5 years, Keros Therapeutics' Return on Invested Capital peaked at 0.06% during Q3 2025, and registered a low of 0.4% during Q3 2022.
  • In the last 4 years, Keros Therapeutics' Return on Invested Capital had a median value of 0.25% in 2021 and averaged 0.22%.
  • The largest annual percentage gain for Keros Therapeutics' Return on Invested Capital in the last 5 years was 2200bps (2021), contrasted with its biggest fall of -10200bps (2021).
  • Keros Therapeutics' Return on Invested Capital (Quarter) stood at 0.25% in 2021, then plummeted by -57bps to 0.4% in 2022, then grew by 4bps to 0.38% in 2024, then skyrocketed by 115bps to 0.06% in 2025.
  • Its Return on Invested Capital stands at 0.06% for Q3 2025, versus 0.0% for Q2 2025 and 0.0% for Q1 2025.